Oleclumab (INN; development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.ClinicalTrial.gov for Oleclumab
This drug was developed by MedImmune/AstraZeneca.Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab, American Medical Association.
References